Helo Return
Endovascular Engineering, Inc. · Decision date Oct 11, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K253717, Helo™ Return, on 2026-10-11, with the application received 11/24/2025. The applicant is Endovascular Engineering, Inc. of Menlo Park, California. The device is listed under classification name Thrombectomy Whole Blood Return System, regulation number 868.5830, product code SHJ, with the regulation medical specialty recorded as Anesthesiology and the 510(k) review panel as Cardiovascular. The submission is a Traditional 510(k), not reviewed by a third party, and not a combination product. SESE means FDA cleared the device as substantially equivalent; it is not a PMA approval.
The record lists clinical trial NCT05597891 and states that no Predetermined Change Control Plan was authorized. The public page does not include the indications for use, the predicate device, a summary of the technological comparison, or the basis for the equivalence finding, so the specific components and any changed items cannot be described from this source. The decision also appears in FDA's final decisions listing for 510(k)s rendered since October 01, 2026, published 11 Oct 2026.
Whether the cleared labeling covers particular clinical uses, and how the device compares with its predicate, remain unknown from the available material and would require the FDA decision documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Anesthesiology
- Decision date
- Oct 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K253717
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Endovascular Engineering, Inc.
- Product code
- SHJ
- Decision code
- SESE
- Decision date
- Oct 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Thrombectomy Whole Blood Return System.
- Applicant
- Endovascular Engineering, Inc.
- Product code
- SHJ
- FDA device class
- 2
FDA decision timeline
K253717 received
Application receipt date recorded by FDA.
K253717 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endovascular Engineering, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Menlo Park, CA
Sources and methodology
- Original FDA record: K253717
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records